paper n a pt3 akt fluc ovap (Addgene inc)
Structured Review
Paper N A Pt3 Akt Fluc Ovap, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plasmid+fluc-+n+-hibit/pUPD-pHXT7+(01-11)+(Plasmid+%23101686)/pmc11384939__mmc2-242-250-246
Average 93 stars, based on 1 article reviews
Images
Related Articles
Construct:Article Title: A pro-metastatic tRNA fragment drives Nucleolin oligomerization and stabilization of its bound metabolic mRNAs. Article Snippet: Article .. Article .. Article Software:Article Title: m 6 A-driven SF3B1 translation control steers splicing to direct genome integrity and leukemogenesis. Article Snippet: Phoenix Ampho ATCC RRID: CVCL_H716 Experimental models: Organisms/strains Mouse: C57BL/6-Tg(Vav1-NUP98/HOXD13) G2Apla/J (NHD13) Jackson Laboratories CAT#010505 Mouse: NOD/SCID/g Jackson Laboratories CAT#005557 Mouse: C57/Bl6/SvJ Lund University N/A Oligonucleotides Oligonucleotides for qPCR analysis and genome editing in Table S9 This paper N/A Recombinant DNA pLCV.2 TRE_c-MYC EF1a_rtTA_P2A_PuroCrRED This paper N/A pLKO.1 TRC U6_shCTR hPGK_eGFP This paper N/A pLKO.1 TRC U6_shSF3B1 (hsa) hPGK_eGFP This paper N/A pLKO.1 TRC U6_shSF3B1 (mms) hPGK_eGFP This paper N/A Monocistronic SF3B1 5’UTR WT This paper N/A Monocistronic SF3B1 5’UTR WT ‘m6A-low’ This paper N/A Monocistronic SF3B1 5’UTR A88GMUT This paper N/A Monocistronic SF3B1 5’UTR A88GMUT ‘m6A-low’ This paper N/A Monocistronic SF3B1 5’UTR C89T MUT This paper N/A Monocistronic SF3B1 5’UTR uORF1MUT This paper N/A Monocistronic SF3B1 5’UTR uORF2MUT This paper N/A (Continued on next page) ll OPEN ACCESSArticle Molecular Cell 83, 1165–1179.e1–e11, April 6, 2023 e4 .. REAGENT or RESOURCE SOURCE IDENTIFIER pBABE HRasV12 Bellodi et al.74 N/A pBABE SF3B1 5’UTR WT-Fluc-3xMS2 Hygro This paper N/A pBABE SF3B1 5’UTR A88GMUT-Fluc-3xMS2 Hygro This other:Article Title: Lysosomal cystine governs ferroptosis sensitivity in cancer via cysteine stress response. Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Slc7a11 shRNA primer #1 (mouse): CGAACAAAAAAGCAGGCGGTACCGAATCAGCCT CGAGGCTGATTCGGTACCGCCTGCC IDT N/A Slc7a11 shRNA primer #2 (mouse): ACCGGGAGGGAAACTAAAAATGGAGCTCGAGCT CCATTTTTAGTTTCCCTCTTTTTTG IDT N/A Slc7a11 shRNA primer #2 (mouse): CGAACAAAAAAGAGGGAAACTAAAAATGGAGC TCGAGCTCCATTTTTAGTTTCCCTCC IDT N/A Slc7a11 shRNA primer #1 (human): ACCGGGGTGTTTCTGAGTAGTAATTACTCGAGTA ATTACTACTCAGAAACACCTTTTTTG IDT N/A Slc7a11 shRNA primer #1 (human): CGAACAAAAAAGGTGTTTCTGAGTAGTAATTA CTCGAGTAATTACTACTCAGAAACACCC IDT N/A AhR shRNA primer #1 (mouse): ACCGGTGAGGTGCCTGCTGGATAATTCTCGAGAA TTATCCAGCAGGCACCTCATTTTTTG IDT N/A AhR shRNA primer #1 (mouse): CGAACAAAAAATGAGGTGCCTGCTGGATAATTC TCGAGAATTATCCAGCAGGCACCTCAC IDT N/A AhR shRNA primer #2 (mouse): ACCGGCAGAGCTCTTTCCGGATAATACTCGA GTATTATCCGGAAAGAGCTCTGTTTTTTG IDT N/A AhR shRNA primer #2 (mouse): CGAACAAAAAACAGAGCTCTTTCCGGATAAT ACTCGAGTATTATCCGGAAAGAGCTCTGC IDT N/A pAtf4 (-1200bp) F: ATTGACTAGTACGCCTGGGCC AATCAGCTCGAC IDT N/A pAtf4 (-1000bp) F: ATTGACTAGTTCTCATGGGGCCTT TAGGACGAT IDT N/A pAtf4 (-800bp) F: ATTGACTAGTCATTTCTGCTTGCTG TCTGCCGG IDT N/A pAtf4 (-500bp) F: ATTGACTAGTGCGTTGCCTGCGACG CCGGCGCT IDT N/A pAtf4 (-400bp) F: ATTGACTAGTGCTCACCGGGGTCC CCGTGTCAT IDT N/A pAtf4 (-300bp) F: ATTGACTAGTCGTATTAGGACGCGA GGACAAGC IDT N/A pAtf4 (-200bp) F: ATTGACTAGTCACAATGGCCTTGGG CCCGCGTG IDT N/A pAtf4 (-100bp) F: ATTGACTAGTCCATCCAGGCTCTTC ACGAAATC IDT N/A pAtf4 (-400bp) R: ATGCGGATCCCCCGAGATGATTAA GCTAAGACA IDT N/A pAtf4 (-800bp) R: ATGCGGATCCGGCGGCGGCACGCCC TAAACCCG IDT N/A pAtf4 (-1000bp) R: ATGCGGATCCAGAAAAGTGCACTACT TTATAGG IDT N/A pAtf4 (0bp) R: Article Title: MAPK14/p38α shapes the molecular landscape of endometrial cancer and promotes tumorigenic characteristics. Article Snippet: Pa02C ATCC N/A Pa03C ATCC N/A FaDU ATCC N/A KYSE-30 UNC Tissue Culture Facility N/A Oligonucleotides sgRNA sequences This paper Table S3 qRT-PCR primer This paper Table S3 Article Title: Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8 T cell exhaustion and anti-PD-1 resistance Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER human Tim3 primer 2 Reverse primer (50-30): CTGCTACTGCATTTGCCAATCCTG Beijing Tsingke Biotech Co., Ltd. N/A h-ADAM10 Forward primer (50-30): TGGTGGCACATTTTATGTTGAGC Beijing Tsingke Biotech Co., Ltd. N/A h-ADAM10 Reverse primer (50-30): AAGTTCTGGACCATTAGCAGC Beijing Tsingke Biotech Co., Ltd. N/A h-ADAM 17 Forward primer (50-30): GACTCTAGGGTTCTAGCCCAC Beijing Tsingke Biotech Co., Ltd. N/A h-ADAM 17 Reverse primer (50-30): GGAGACTGCAAACGTGAAACAT Beijing Tsingke Biotech Co., Ltd. N/A mIFN-g Forward primer (50-30): TGAGTATTGCCAAGTTTGAGGTCA Beijing Tsingke Biotech Co., Ltd. N/A mIFN-g Reverse primer (50-30): CGGCAACAGCTGGTGGAC Beijing Tsingke Biotech Co., Ltd. N/A mTNF-a Forward primer (50-30): AGTGACAAGCCTGTAGCCC Beijing Tsingke Biotech Co., Ltd. N/A mTNF-a Reverse primer (50-30): GAGGTTGACTTTCTCCTGGTAT Beijing Tsingke Biotech Co., Ltd. N/A mIL-2 Forward primer (50-30): GGAGCAGCTGTTGATGGACCTAC Beijing Tsingke Biotech Co., Ltd. N/A mIL-2 Reverse primer (50-30): AATCCAGAACATGCCGCAGAG Beijing Tsingke Biotech Co., Ltd. N/A m18S Forward primer (50-30): AGTTCCAGCACATTTTGCGAG Beijing Tsingke Biotech Co., Ltd. N/A m18S Reverse primer (50-30): TCATCCTCCGTGAGTTCTCCA Beijing Tsingke Biotech Co., Ltd. N/A h-bActin Forward primer (50-30): AGTTGCGTTACACCCTTTC Beijing Tsingke Biotech Co., Ltd. N/A h-bActin Reverse primer (50-30): CCTTCACCGTTCCAGTTT Beijing Tsingke Biotech Co., Ltd. N/A shCEACAM-1 sense: TGGGAGTCTACACACTAGATA Beijing Tsingke Biotech Co., Ltd. N/A shCEACAM-1 anti-sense: TATCTAGTGTGTAGACTCCCA Beijing Tsingke Biotech Co., Ltd. N/A sgCEACAM-1: TTCACGGGGCAAGCATACAG Beijing Tsingke Biotech Co., Ltd. N/A Recombinant DNA pT3/NICD1 Addgene (Gift from Xin Chen) #86500 pCMV( Article Title: RNF10 and RIOK3 facilitate 40S ribosomal subunit degradation upon 60S biogenesis disruption or amino acid starvation. Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Critical commercial assays BCA Protein Assay Thermo Scientific (Pierce) Cat# 23225 CellTiter-Glo 2.0 Cell Viability Assay Promega Cat# G9243 Dual-Glo Luciferase Assay System Promega Cat# E2940 Deposited data 60S biogenesis knockdown proteomics (S3A-S3D, Figures 1F and 2A-C, 3A–3C, 6A; S1F; S2A) This paper PRIDE: PXD060355 Sucrose gradient siGTPBP4 proteomics (Figure 2F) This paper PRIDE: PXD060349 RNF10 KO with 60S biogenesis knockdown proteomics (Figures 3C and 5A, S3F-S3G, S6A) This paper PRIDE: PXD060309 eIF4A1 and GTPBP4 co-knockdown proteomics (Figures 4A and 4C; S4A) This paper PRIDE: PXD060375 RNF10 OE with eIF4A1 knockdown proteomics (Figures 4D, S4D) This paper PRIDE: PXD060334 GTPBP4 and NFX1/NFXL1 co-knockdown proteomics (Figures 5A, S5A-S5B) This paper PRIDE: PXD060331 eRQC factors and GTPBP4 co-knockdown proteomics (Figure 5B, S5C-S5E) This paper PRIDE: PXD060206 DBA-related proteins knockdown proteomics (Figures 5C, S5F) This paper PRIDE: PXD060207 40S biogenesis factor and GTPBP4 co-knockdown proteomics (Figures 5E-5F, S5G–S5H) This paper PRIDE: PXD060296 eS26 (RPS26) and GTPBP4 co-knockdown proteomics (Figures 5E-5F, S5G–S5H) This paper PRIDE: PXD060177 RIOK3 and GTPBP4 co-knockdown proteomics (Figures 6B–6D) This paper PRIDE: PXD060208 RNF10 OE proteomics (Figure S6B) This paper PRIDE: PXD060299 RIOK3 KO with GTPBP4 knockdown proteomics (Figures S6C–S6D) This paper PRIDE: PXD060294 RIOK3 variants rescue proteomics (Figures 7D, S7G) This paper PRIDE: PXD060301 Amino acid starvation in RNF10 KO and RIOK3 KO cell lines proteomics (Figure 7F, S7E–S7F, S7H–S7I) This paper PRIDE: PXD060308 Experimental models: Cell lines HEK293T ATCC Cat# CRL-3216 293Flp-In T-REx Thermo Fisher Scientific Cat# R78007 HAP1 Johnson et al.79 N/A OVTOKO JCRB Cell Bank Cat# JCRB1048 293FlpIn-RNF10KO Garshott et al.17 N/A 293FlpIn-FRT-Flag-HA-RNF10wt Garshott et al.17 N/A 293FlpIn-RIOK3KO_C4 This paper N/A 293FlpIn-Flag-HA-RIOK3-WT-siRes This paper N/A 293FlpIn-Flag-HA-RIOK3-DN-siRes This paper N/A 293FlpIn-Flag-HA-RIOK3-KM-siRes This paper N/A Oligonucleotides For oligonucleotides, see Table S1 Article Title: Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8 + T cell exhaustion and anti-PD-1 resistance. Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER human Tim3 primer 2 Reverse primer (50-30): CTGCTACTGCATTTGCCAATCCTG Beijing Tsingke Biotech Co., Ltd. N/A h-ADAM10 Forward primer (50-30): TGGTGGCACATTTTATGTTGAGC Beijing Tsingke Biotech Co., Ltd. N/A h-ADAM10 Reverse primer (50-30): AAGTTCTGGACCATTAGCAGC Beijing Tsingke Biotech Co., Ltd. N/A h-ADAM 17 Forward primer (50-30): GACTCTAGGGTTCTAGCCCAC Beijing Tsingke Biotech Co., Ltd. N/A h-ADAM 17 Reverse primer (50-30): GGAGACTGCAAACGTGAAACAT Beijing Tsingke Biotech Co., Ltd. N/A mIFN-g Forward primer (50-30): TGAGTATTGCCAAGTTTGAGGTCA Beijing Tsingke Biotech Co., Ltd. N/A mIFN-g Reverse primer (50-30): CGGCAACAGCTGGTGGAC Beijing Tsingke Biotech Co., Ltd. N/A mTNF-a Forward primer (50-30): AGTGACAAGCCTGTAGCCC Beijing Tsingke Biotech Co., Ltd. N/A mTNF-a Reverse primer (50-30): GAGGTTGACTTTCTCCTGGTAT Beijing Tsingke Biotech Co., Ltd. N/A mIL-2 Forward primer (50-30): GGAGCAGCTGTTGATGGACCTAC Beijing Tsingke Biotech Co., Ltd. N/A mIL-2 Reverse primer (50-30): AATCCAGAACATGCCGCAGAG Beijing Tsingke Biotech Co., Ltd. N/A m18S Forward primer (50-30): AGTTCCAGCACATTTTGCGAG Beijing Tsingke Biotech Co., Ltd. N/A m18S Reverse primer (50-30): TCATCCTCCGTGAGTTCTCCA Beijing Tsingke Biotech Co., Ltd. N/A h-bActin Forward primer (50-30): AGTTGCGTTACACCCTTTC Beijing Tsingke Biotech Co., Ltd. N/A h-bActin Reverse primer (50-30): CCTTCACCGTTCCAGTTT Beijing Tsingke Biotech Co., Ltd. N/A shCEACAM-1 sense: TGGGAGTCTACACACTAGATA Beijing Tsingke Biotech Co., Ltd. N/A shCEACAM-1 anti-sense: TATCTAGTGTGTAGACTCCCA Beijing Tsingke Biotech Co., Ltd. N/A sgCEACAM-1: TTCACGGGGCAAGCATACAG Beijing Tsingke Biotech Co., Ltd. N/A Recombinant DNA pT3/NICD1 Addgene (Gift from Xin Chen) #86500 pCMV( Article Title: Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity. Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Experimental models: Organisms/strains Mus musculus FVB/NRj Janvier Labs N/A Mus musculus C57BL/6-Tg(TcraTcrb) 1100Mjb/J The Jackson laboratory 003831 Mus musculus NOD/SCID/IL2rg / The Netherlands Cancer Institute N/A Mus musculus FVB/NRj ROSA26mTmG The Netherlands Cancer Institute N/A Mus musculus K14-Cre; Brca1fl/fl; p53 fl/fl (KB1P) Described by Duarte et al., 2018.23 Obtained from the group of Jos Jonkers at the Netherlands Cancer Institute N/A Mus musculus MMTV-PyMT Described by Lin et al., 2003,24 obtained from The Jackson laboratory 022974 Biological samples K14-Cre; Brca1fl/fl; p53 fl/fl (KB1P) organoids Described by Duarte et al., 201823 N/A MMTV-PyMT organoids Described by Lin et al., 200324 N/A Organoids isolated from patients with breast cancer 13T; 27T; 38T; 62T; 100T; 169M; 36T Described by Sachs et al., 201833 and Dekkers et al., 202134 N/A Healthy human breast organoids m12 Described by Sachs et al., 201833 and Dekkers et al., 202134 N/A Organoids isolated from patients with NSCLC or CRC Described by Dijkstra et al., 201840 and Cattaneo et al., 202039 N/A T cells isolated from patients with NSCLC or CRC Described by Dijkstra et al., 201840 and Cattaneo et al., 202039 N/A Recombinant DNA ABCB1 ORF The Netherlands Cancer Institute See Annex 2 for map plv-OVA-mPlum Gift from the Peeper lab, the Netherlands Cancer Institute N/A pLenti CMV Puro LUC Addgene w168–1; Plasmid #17477 |
